Volume Spike Investor

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is surging on reports that it completed its Phase 1 clinical trial and initiated Phase 2 clinical trial of LX4211 in patients with type 2 diabetes.  The results in normal healthy volunteers were well tolerated at all dose levels and produced a dose-dependent increase in urinary glucose excretion. It also demonstrated a favorable pharmacokinetic profile supporting the potential for once daily dosing. The four-week, randomized, double-blind, placebo-controlled study will be conducted in the United States and is expected to enroll 36 patients with type 2 diabetes. At 8:40 AM EST we have seen shares pop up 31% to $2.13 on 105,000 shares,  Average volume is 180,000 shares.  Be advised that the prior 52-week high is $2.15, so that is right here ate current pre-market prices.  JON OGG